{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:13:49Z","timestamp":1791389629950,"version":"4.3.3"},"reference-count":30,"publisher":"Elsevier BV","issue":"44","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.vaccine.2019.08.087","type":"journal-article","created":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T17:10:35Z","timestamp":1568999435000},"page":"6760-6767","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Adverse events following adenovirus type 4 and type 7 vaccine, live, oral in the Vaccine Adverse Event Reporting System (VAERS), United States, October 2011\u2013July 2018"],"prefix":"10.1016","volume":"37","author":[{"given":"Michael M.","family":"McNeil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iwona","family":"Paradowska-Stankiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine R.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paige L.","family":"Marquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srihari","family":"Seshadri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Limone C.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria V.","family":"Cano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.08.087_b0005","series-title":"Douglas and Bennett\u2019s principles and practice of infectious diseases","article-title":"Adenoviruses","author":"Rhee","year":"2009"},{"key":"10.1016\/j.vaccine.2019.08.087_b0010","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1093\/infdis\/156.6.920","article-title":"Adenovirus infections and respiratory illnesses in children in group day care","volume":"156","author":"Pacini","year":"1987","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.08.087_b0015","series-title":"Viral infections of humans: epidemiology and control","first-page":"119","article-title":"Adenoviruses","author":"Foy","year":"1997"},{"key":"10.1016\/j.vaccine.2019.08.087_b0020","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3201\/eid0604.000419","article-title":"Epidemic spread of adenovirus type 4-associated acute respiratory disease between US Army installations","volume":"6","author":"McNeill","year":"2000","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2019.08.087_b0025","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1086\/342573","article-title":"Large epidemic of adenovirus type 4 infection among military trainees; epidemiological, clinical, and laboratory studies","volume":"35","author":"Kolavic-Gray","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2019.08.087_b0030","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1086\/338471","article-title":"Large epidemic of respiratory illness due to adenovirus types 7 and 3 in healthy young adults","volume":"34","author":"Ryan","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2019.08.087_b0035","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1086\/522188","article-title":"Genotype prevalence and risk factors for severe clinical adenovirus infection, United States 2004\u20132006","volume":"45","author":"Gray","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2019.08.087_b0040","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/oxfordjournals.aje.a121499","article-title":"Acute respiratory disease in military trainees: the adenovirus surveillance program, 1966\u20131971","volume":"97","author":"Dudding","year":"1973","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2019.08.087_b0045","first-page":"29","article-title":"Appraisal of occurrence of adenovirus-caused respiratory illness in military populations","volume":"66","author":"Hillemann","year":"1957","journal-title":"Am J Hyg"},{"key":"10.1016\/j.vaccine.2019.08.087_b0050","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1086\/313999","article-title":"Adult adenovirus infections: loss of orphaned vaccines precipitates military respiratory disease epidemics. For the Adenovirus Surveillance group","volume":"31","author":"Gray","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2019.08.087_b0055","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1016\/j.vaccine.2005.12.062","article-title":"Vaccine-preventable adenoviral respiratory illness in US military recruits, 1999\u20132004","volume":"24","author":"Russell","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.08.087_b0060","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3201\/eid1803.111238","article-title":"Adenovirus-associated deaths in US military during postvaccination period, 1999\u20132010","volume":"18","author":"Potter","year":"2012","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2019.08.087_b0065","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1016\/j.vaccine.2008.03.037","article-title":"A double-blind, placebo-controlled study of the safety and immunogenicity of live, oral type 4 and type 7 adenovirus vaccine in adults","volume":"26","author":"Lyons","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.08.087_b0070","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1016\/j.vaccine.2013.04.035","article-title":"A phase 3, randomized, double-blind, placebo-controlled study of the safety and efficacy of the live, oral adenovirus type4 and type 7 vaccine, in military recruits","volume":"31","author":"Kuschner","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.08.087_b0075","unstructured":"Food and Drug Administration. Adenovirus Type 4 and Type 7 Vaccine, Live, Oral. Available: https:\/\/www.fda.gov\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/ucm247508.htm."},{"key":"10.1016\/j.vaccine.2019.08.087_b0080","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1093\/cid\/ciu507","article-title":"Dramatic decline of respiratory illness among US military recruits after the renewed use of adenovirus vaccines","volume":"59","author":"Radin","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2019.08.087_b0085","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.2105\/AJPH.92.12.1900","article-title":"The Defense Medical Surveillance System and the Department of Defense serum repository: glimpses of the future of public health surveillance","volume":"92","author":"Rubertone","year":"2002","journal-title":"Am J Public Health"},{"key":"10.1016\/j.vaccine.2019.08.087_b0090","doi-asserted-by":"crossref","first-page":"4558","DOI":"10.1016\/j.vaccine.2016.07.033","article-title":"Safety evaluation of adenovirus type 4 and type 7 vaccine live, oral in military recruits","volume":"34","author":"Choudhry","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.08.087_b0095","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1016\/j.vaccine.2015.07.035","article-title":"Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS)","volume":"33","author":"Shimabukuro","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.08.087_b0100","unstructured":"Medical Dictionary for Regulatory Activities. Available at: http:\/\/www.meddra.org\/."},{"key":"10.1016\/j.vaccine.2019.08.087_b0105","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals. Available: http:\/\/www.ich.org\/products\/meddra.html."},{"key":"10.1016\/j.vaccine.2019.08.087_b0110","unstructured":"Food and Drug Administration. 21 CFR Part 600.80. Postmarketing reporting of adverse experiences. Vol 62: Federal Register. 1997:52252\u20133."},{"key":"10.1016\/j.vaccine.2019.08.087_b0115","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1016\/j.vaccine.2007.02.064","article-title":"Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of safety data","volume":"25","author":"R\u00fcggerberg","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.08.087_b0120","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.vaccine.2010.06.003","article-title":"Guillain-Barr\u00e9 syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data","volume":"29","author":"Sejvar","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.08.087_b0125","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1385\/NMM:8:1-2:159","article-title":"Inherited focal, episodic neuropathies: hereditary neuropathy with liability to pressure palsies and hereditary neuralgic amyotrophy","volume":"8","author":"Chance","year":"2006","journal-title":"Neuromolecular Med"},{"key":"10.1016\/j.vaccine.2019.08.087_b0130","unstructured":"BUMEDINST 6220.8b. Recruit streptococcal infection prevention program. Dept. of the Navy. 20 June 2014 at https:\/\/www.med.navy.mil\/directives\/ExternalDirectives\/6220.8B.pdf."},{"key":"10.1016\/j.vaccine.2019.08.087_b0135","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4103\/2231-4040.70513","article-title":"The facts about penicillin allergy","volume":"1","author":"Bhattacharya","year":"2010","journal-title":"J Adv Pharm Technol Res"},{"key":"10.1016\/j.vaccine.2019.08.087_b0140","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/oxfordjournals.aje.a112795","article-title":"Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976\u20131977","volume":"110","author":"Schonberger","year":"1979","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2019.08.087_b0145","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/CND.0000000000000145","article-title":"Acute demyelinating polyneuropathy as presentation of hereditary neuropathy with liability to pressure palsies in a patient who exercised regularly in the Army","volume":"18","author":"Perugula","year":"2017","journal-title":"J Clin Neuromuscul Dis"},{"key":"10.1016\/j.vaccine.2019.08.087_b0150","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1136\/jnnp.2003.029314","article-title":"Hereditary neuropathy with liability to pressure palsy: fulminant development with axonal loss during military training","volume":"75","author":"Horowitz","year":"2004","journal-title":"J Neurol Neurosurg Psychiatr"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19311880?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19311880?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:35:51Z","timestamp":1759401351000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19311880"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":30,"journal-issue":{"issue":"44","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S0264410X19311880"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.08.087","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adverse events following adenovirus type 4 and type 7 vaccine, live, oral in the Vaccine Adverse Event Reporting System (VAERS), United States, October 2011\u2013July 2018","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.08.087","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}